Skip to content
Screener

Stryker SYK Endoscopy — Net Sales

Other product segments

Trauma and Extremities
$1.04B+9.5%
Instruments
$920M+9.8%
Medical
$902M-4.6%
Knees
$670M+4.9%
Ortho Tech
$646M—
Vascular
$517M+27.3%
Hips
$460M+3.8%
Spine
$8M-95.7%

Similar metrics at other companies

Boston Scientific logo
BSXEndoscopy — Net Sales
$736M+9.4%
POS
POSTNut butters — Net Sales
$101.3M+392%
POS
POSTPet Food — Net Sales
$346.7M-19.9%
Otis Worldwide logo
OTISService sales — Net Sales
$2.58B+11.3%
Central Garden & Pet Company logo
CENTPet — Net Sales
$476.84M+5.1%
Central Garden & Pet Company logo
CENTOther pet products — Net Sales
$164M+7.3%

Other financials

Income statement

See full
Revenue$6.6B+9.4%
Gross profit$4.5B+17.1%
Operating income$1.7B+49.1%
Net income$1.3B+44.3%
EPS (diluted)$3.30+44.1%

Balance sheet

See full
Cash & equivalents$3.4B+42.8%
Total debt$14.2B-15.2%
Total assets$47.9B+3.5%

Cash flow

See full
Operating cash flow$1.3B+13.5%
CapEx$202.0M+10.4%
Free cash flow$1.1B+14.1%

Valuation

See full
Market cap$124.86B-14.4%
Enterprise value$135.66B-15.3%
P/E33.5×-16.5×
P/S4.8×-1.3×

Profitability

See full
Gross margin65%+0.8pp
Operating margin21.4%+6.2pp
Net margin14.4%+2.2pp
FCF margin18.2%+1.3pp

Returns & leverage

See full
Return on equity32.8%—
Debt / equity0.8×—
Current ratio2.2×+0.4×

Where this comes from

Reported directly by Stryker in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Stryker’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 11:10 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000310764-26-000031
Net Sales by BusinessThree Months / 2026Three Months / 2025
MedSurg and Neurotechnology:
Instruments$920$838
Endoscopy868867
Medical902945
Vascular517406
$3,207$3,056
Orthopaedics:
Knees$670$639

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Stryker's endoscopy — net sales?
Stryker (SYK) reported endoscopy — net sales of $868M in Q1 2026.
How has Stryker's endoscopy — net sales changed year-over-year?
Stryker's endoscopy — net sales increased by 0.1% year-over-year, from $867M to $868M.
What is the long-term trend for Stryker's endoscopy — net sales?
Over 4 years (2021 to 2025), Stryker's endoscopy — net sales has grown at a 12.0% compound annual growth rate (CAGR), from $2.42B to $3.81B.
What does endoscopy — net sales mean?
This metric represents the total revenue generated from the sale of endoscopy systems, visualization equipment, and related surgical instruments. It reflects the company's market performance in minimally invasive surgical technology and the adoption rates of its advanced imaging platforms within hospital and ambulatory surgery center settings. This segment is a critical driver of the company's surgical technology portfolio and overall growth strategy.

Ask your AI about Stryker's endoscopy — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude